AI Biotechnology LLC → Yarrow Bioscience, Inc. VYNE

The disclosure in Item 4 is hereby amended and supplemented by adding the following at the end thereof: On July 27, 2026, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, as amended by Amendment No. 1 thereto on January 30, 2026, by and among VYNE Therapeutics Inc., Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of VYNE Therapeutics Inc., and Yarrow Bioscience, Inc., a Delaware corporation ("Pre-Merger Yarrow"), Yellow Merger Sub Corp. merged with and into Pre-Merger Yarrow, with Pre-Merger Yarrow continuing as a wholly owned subsidiary of VYNE Therapeutics Inc. and the surviving corporation of the merger (the "Merger"). In connection with the completion of the Merger, VYNE Therapeutics Inc. changed its name to Yarrow Bioscience, Inc. Prior to the consummation of the Merger, the Issuer effected a 1-for-50 reverse stock split of its Common Stock by filing a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became legally effective on July 24, 2026 (the "Reverse Stock Split"). Upon the effectiveness of the Reverse Stock Split, every 50 shares of Common Stock issued and outstanding immediately prior thereto were automatically and without further action on the part of the Issuer or any holders of Common Stock combined into one share of Common Stock. No fractional shares were issued as a result of the Reverse Stock Split. Instead, any stockholder who would otherwise have been entitled to a fractional share, after aggregating all fractions of a share to which such stockholder would otherwise have been entitled, became entitled to receive a cash payment equal to the product of the resulting fractional interest in one share of Common Stock multiplied by the closing price per share as reported by Nasdaq on July 23, 2026. As a result of the Reverse Stock Split, the 1,116,585 shares of Common Stock held by AI Biotechnology were combined into 22,331 whole shares of Common Stock, and AI Biotechnology became entitled to receive cash in lieu of the resulting 0.70 fractional share. In addition, pursuant to the terms of the Warrants, the exercise price of the Warrants and the number of shares of Common Stock issuable upon exercise thereof were proportionately adjusted, with the number of shares of Common Stock issuable upon exercise of the Warrants being adjusted from 7,792,448 shares to 155,849 shares.